Amivantamab plus Chemotherapy in NSCLC with EGFR …
Oct 21, 2023 · We conducted the phase 3, international, randomized PAPILLON trial to assess the efficacy and safety of amivantamab–chemotherapy as compared with standard chemotherapy alone as first-line ...
Amivantamab plus Chemotherapy in NSCLC with - PubMed
Nov 30, 2023 · The use of amivantamab-chemotherapy resulted in superior efficacy as compared with chemotherapy alone as first-line treatment of patients with advanced NSCLC with EGFR …
Amivantamab plus chemotherapy with and without …
MARIPOSA-2 is a global, randomized, phase III trial assessing the efficacy and safety of amivantamab–chemotherapy and amivantamab–lazertinib–chemotherapy versus chemotherapy in patients with …
Treatment with RYBREVANT® (amivantamab-vmjw) Plus …
Jul 17, 2023 · PAPILLON (NCT04538664) is a randomized, open-label Phase 3 study evaluating the efficacy and safety of RYBREVANT ® in combination with chemotherapy, compared with …
PAPILLON: Adding Amivantamab to First-Line …
December 10, 2023. In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with …
Papillon Trial | RYBREVANT® (amivantamab-vmjw)
Learn about the RYBREVANT® (amivantamab-vmjw) Papillon clinical trial, its study design, and the outcomes. See Full Prescribing & Safety Information.
P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab …
The primary objective of this phase 3 randomized, open-label study is to compare the efficacy of amivantamab in combination with chemotherapy (amivantamab/carboplatin/pemetrexed) …
FDA Accepts sBLA for Amivantamab/Chemo in EGFR Exon 20
Aug 25, 2023 · Investigators of the open-label, randomized PAPILLON trial are assessing the safety and efficacy of amivantamab plus chemotherapy vs chemotherapy alone in patients …
PAPILLON Study Meets Clinical End Point in Patients …
Jul 17, 2023 · Amivantamab-vmjw (Rybrevant) showed efficacy in a phase 3 trial of patients with newly diagnosed advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
Oct 21, 2023 · In this phase 3, international, randomized trial, we assigned in a 1:1 ratio patients with advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic …
